On November 23, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) reported that it plans to host a conference call and webcast at 4:30 pm ET on Tuesday, November 24, 2015 to discuss the ICT-107 program in patients with newly diagnosed glioblastoma, including recently reported updated phase 2 clinical trial results and the design of the phase 3 registrational program (Press release, ImmunoCellular Therapeutics, NOV 23, 2015, View Source [SID:1234508335]). The conference call and webcast will be hosted by Andrew Gengos, President and CEO.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LIVE CALL: (877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 89218581

WEBCAST: Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular’s website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.